Ono Pharmaceutical Enters into Collaboration Agreement with Domain Therapeutics and University of Montreal for GPCR Targeted Drug Discovery

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; ‘Ono’) announced that it had recently signed a collaboration agreement with Therapeutic Area SA (Strasbourg, France; CEO: Pascal Neuville; ‘Domain’) and University of Montreal (Quebec, Canada; ‘UdM’), to discover novel small molecules targeting G protein-coupled receptors (GPCRs) in a field of metabolic diseases.

Under this agreement, Ono will collaborate with Domain and UdM using bioSens-All technology’s GPCR drug discovery platform, licensed from Domain from UdM, and their expertise in medicinal chemistry and pharmacology GPCR to design and optimize innovative small molecules against a selected GPCR. as a therapeutic target by Ono, for a future drug development program.

Ono will have exclusive worldwide rights to develop and commercialize any pharmaceutical products resulting from the drug discovery collaboration. Ono will provide Domain and UdM with an upfront payment, research funding for collaborative research programs, milestones based on the success of research and development progress, and royalties from future sales.

We highly value Domain and UdM’s bioSens-All technology platform for the detection of GPCR proximal signaling pathways,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of Ono. “We look forward to collaborating with Domain and UdM, which have world-renowned scientists for GPCR research, to create and bring innovative therapeutic drugs to patients with metabolic diseases as soon as possible. unsatisfied doctors.”

At Domain, we are delighted to strengthen our long-term relationship with Ono pharma and UdM,” commented Stephane Schann, Vice President of Research and Partnerships at Domain Therapeutics. “The bioSens-All technology platform is a disruptive approach to approaching GPCR drug discovery.”

Very early on, we accumulated great expertise on GPCR and its pharmacology,” notes Michael BouvierCEO of IRIC, University of from Montreal Institute for Research in Immunology and Cancer. “This new alliance establishes a strong link between our research team, Domain Therapeutics, a long-time partner, and Ono Pharmaceuticalsour new strategic partner, for the benefit of patients suffering from metabolic diseases.’

About the GPCR

GPCRs are members of a class of G protein-conjugated cell surface receptors, whose signaling pathway is initiated by binding between the receptor and a hormone or bioactive molecule. GPCR-targeted therapies include major classes of drugs in many disease areas, including CNS, metabolic, cardiovascular, respiratory, urinary, and gastrointestinal diseases.

About Domain Therapeutics

Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and development of new drug candidates targeting GPCRs, one of the most important classes of drug targets. Over the past decade, the company has created a proprietary pipeline of GPCR targeting assets. The company’s objective is to sign multiple partnership agreements with pharmaceutical companies bringing its expertise and technology in the field of GPCRs while developing its own pipeline of proprietary assets in immuno-oncology.

bioSens-All provides drug discovery teams with the ability to interrogate direct proximal signaling events covering key effectors engaged during GPCR activation. bioSens-All enables deeper understanding of proximal signaling profiles, providing a functional readout to assess small molecule or antibody activities based on physiologically relevant signaling information. For more information : https://www.domaintherapeutics.com/

About the University of Montreal

Deeply rooted in Montreal and dedicated to its international mission, the University of Montreal ranks among the best universities in the world, especially in the French-speaking world. Founded in 1878, the University of Montreal today has 16 faculties and with its two affiliated schools, HEC Montréal and Polytechnic universityconstitutes the largest pole of higher education and research Quebec and one of the main centers of North America. It brings together 2,600 teacher-researchers and more than 65,000 students.


Business communication

Email: [email protected]

Comments are closed.